Cantor Fitzgerald Issues Positive Estimate for TSHA Earnings

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) – Investment analysts at Cantor Fitzgerald boosted their FY2025 earnings estimates for Taysha Gene Therapies in a research note issued on Thursday, February 27th. Cantor Fitzgerald analyst K. Kluska now forecasts that the company will post earnings per share of ($0.38) for the year, up from their prior estimate of ($0.40). Cantor Fitzgerald has a “Overweight” rating and a $7.00 price objective on the stock. The consensus estimate for Taysha Gene Therapies’ current full-year earnings is ($0.35) per share.

Taysha Gene Therapies (NASDAQ:TSHA) last issued its earnings results on Wednesday, February 26th. The company reported ($0.07) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.01. Taysha Gene Therapies had a negative net margin of 229.67% and a negative return on equity of 106.36%. The company had revenue of $2.02 million during the quarter, compared to analysts’ expectations of $2.05 million.

A number of other research analysts have also recently issued reports on TSHA. Chardan Capital reaffirmed a “buy” rating and issued a $7.00 target price on shares of Taysha Gene Therapies in a report on Wednesday, February 26th. Needham & Company LLC reiterated a “buy” rating and issued a $6.00 price target on shares of Taysha Gene Therapies in a research report on Thursday, February 27th. JMP Securities reiterated a “market outperform” rating and issued a $5.00 price target on shares of Taysha Gene Therapies in a research report on Tuesday, November 12th. Finally, Canaccord Genuity Group increased their price target on shares of Taysha Gene Therapies from $6.00 to $8.00 and gave the company a “buy” rating in a research report on Friday, November 15th. Eight research analysts have rated the stock with a buy rating, According to MarketBeat, the company has an average rating of “Buy” and a consensus target price of $6.63.

Taysha Gene Therapies Trading Up 1.3 %

Shares of Taysha Gene Therapies stock opened at $1.62 on Monday. Taysha Gene Therapies has a 12-month low of $1.19 and a 12-month high of $4.32. The company has a current ratio of 5.51, a quick ratio of 5.51 and a debt-to-equity ratio of 0.48. The stock has a market cap of $332.01 million, a PE ratio of 2.57 and a beta of 0.92. The company has a 50-day moving average of $1.67 and a two-hundred day moving average of $1.97.

Institutional Trading of Taysha Gene Therapies

A number of hedge funds have recently bought and sold shares of TSHA. Octagon Capital Advisors LP boosted its position in Taysha Gene Therapies by 128.6% during the fourth quarter. Octagon Capital Advisors LP now owns 10,450,000 shares of the company’s stock worth $18,078,000 after acquiring an additional 5,877,778 shares during the last quarter. Adage Capital Partners GP L.L.C. acquired a new stake in Taysha Gene Therapies during the fourth quarter worth approximately $8,650,000. Bank of America Corp DE boosted its position in Taysha Gene Therapies by 1,178.9% during the fourth quarter. Bank of America Corp DE now owns 1,710,303 shares of the company’s stock worth $2,959,000 after acquiring an additional 1,576,568 shares during the last quarter. Norges Bank acquired a new stake in Taysha Gene Therapies during the fourth quarter worth approximately $2,528,000. Finally, Avoro Capital Advisors LLC boosted its position in Taysha Gene Therapies by 7.2% during the fourth quarter. Avoro Capital Advisors LLC now owns 19,999,999 shares of the company’s stock worth $34,600,000 after acquiring an additional 1,349,999 shares during the last quarter. Institutional investors and hedge funds own 77.70% of the company’s stock.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.